evogene ltd - EVGN

EVGN

Close Chg Chg %
0.97 -0.03 -3.17%

Closed Market

0.94

-0.03 (3.17%)

Volume: 212.88K

Last Updated:

Dec 30, 2025, 4:00 PM EDT

Company Overview: evogene ltd - EVGN

EVGN Key Data

Open

$0.96

Day Range

0.93 - 0.98

52 Week Range

0.93 - 2.42

Market Cap

$8.45M

Shares Outstanding

8.72M

Public Float

8.63M

Beta

1.37

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$0.49

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

56.01K

 

EVGN Performance

1 Week
 
-9.22%
 
1 Month
 
-11.36%
 
3 Months
 
-18.30%
 
1 Year
 
-49.75%
 
5 Years
 
-98.00%
 

EVGN Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 1
Full Ratings ➔

About evogene ltd - EVGN

Evogene Ltd. engages in the development and commercialization of a computer-biological platform for improving the development processes of products in the field of life sciences. It operates through the following segments: Agriculture, Industrial Applications, and Human Health. The Agriculture segment develops seed traits, agrochemical products, and agro biological products to improve plant performance. The Industrial Applications focuses on the development and commercialization of improved castor bean seeds for industrial uses. The Human Health segment involves discovery and development of human microbiome-based therapeutics. The company was founded by Amir Barzilay and Hagai Karchi on October 10, 1999 and is headquartered in Rehovot, Israel.

EVGN At a Glance

Evogene Ltd.
13 Gad Feinstein Street
Rehovot, HaMerkaz 7638517
Phone 972-8-931-1900 Revenue 8.51M
Industry Biotechnology Net Income -16,485,000.00
Sector Health Technology 2024 Sales Growth 50.904%
Fiscal Year-end 12 / 2025 Employees 117
View SEC Filings

EVGN Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 1.252
Price to Book Ratio N/A
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -0.735
Enterprise Value to Sales 1.661
Total Debt to Enterprise Value 0.177

EVGN Efficiency

Revenue/Employee 72,743.59
Income Per Employee -140,897.436
Receivables Turnover 5.939
Total Asset Turnover 0.187

EVGN Liquidity

Current Ratio 1.085
Quick Ratio 0.915
Cash Ratio 0.819

EVGN Profitability

Gross Margin 39.807
Operating Margin -255.364
Pretax Margin -211.562
Net Margin -193.691
Return on Assets -36.245
Return on Equity -310.979
Return on Total Capital -1,567.015
Return on Invested Capital -257.558

EVGN Capital Structure

Total Debt to Total Equity N/A
Total Debt to Total Capital 237.928
Total Debt to Total Assets 6.279
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital 181.939
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Evogene Ltd - EVGN

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
930.00K 1.68M 5.64M 8.51M
Sales Growth
-10.58% +80.11% +236.72% +50.90%
Cost of Goods Sold (COGS) incl D&A
3.00M 3.45M 4.24M 5.12M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
2.23M 2.58M 2.61M 2.50M
Depreciation
1.30M 1.51M 1.64M 1.53M
Amortization of Intangibles
932.00K 1.07M 971.00K 974.00K
COGS Growth
-9.09% +14.93% +22.96% +20.80%
Gross Income
(2.07M) (1.77M) 1.40M 3.39M
Gross Income Growth
+8.40% +14.34% +178.86% +142.17%
Gross Profit Margin
-222.69% -105.91% +24.80% +39.81%
2021 2022 2023 2024 5-year trend
SG&A Expense
29.42M 27.94M 27.79M 25.12M
Research & Development
19.43M 17.53M 18.11M 14.26M
Other SG&A
9.99M 10.42M 9.68M 10.87M
SGA Growth
+19.72% -5.02% -0.54% -9.60%
Other Operating Expense
- - - -
-
Unusual Expense
432.00K 835.00K 209.00K (3.37M)
EBIT after Unusual Expense
(31.92M) (30.55M) (26.60M) (18.36M)
Non Operating Income/Expense
1.89M 1.04M 784.00K 481.00K
Non-Operating Interest Income
291.00K 182.00K 1.25M 957.00K
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
403.00K 241.00K 171.00K 124.00K
Interest Expense Growth
+49.81% -40.20% -29.05% -27.49%
Gross Interest Expense
403.00K 241.00K 171.00K 124.00K
Interest Capitalized
- - - -
-
Pretax Income
(30.43M) (29.75M) (25.99M) (18.01M)
Pretax Income Growth
-16.27% +2.23% +12.66% +30.71%
Pretax Margin
-3,272.26% -1,776.36% -460.76% -211.56%
Income Tax
13.00K 90.00K (33.00K) 9.00K
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(30.45M) (29.84M) (25.95M) (18.05M)
Minority Interest Expense
(2.65M) (3.21M) (2.08M) (1.57M)
Net Income
(27.79M) (26.64M) (23.88M) (16.49M)
Net Income Growth
-18.91% +4.16% +10.36% +30.96%
Net Margin Growth
-2,988.49% -1,590.33% -423.39% -193.69%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(27.79M) (26.64M) (23.88M) (16.49M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(27.79M) (26.64M) (23.88M) (16.49M)
EPS (Basic)
-6.8738 -6.4639 -5.2268 -2.8935
EPS (Basic) Growth
+17.19% +5.96% +19.14% +44.64%
Basic Shares Outstanding
4.04M 4.12M 4.57M 5.70M
EPS (Diluted)
-6.8738 -6.4639 -5.2268 -2.8935
EPS (Diluted) Growth
+17.19% +5.96% +19.14% +44.64%
Diluted Shares Outstanding
4.04M 4.12M 4.57M 5.70M
EBITDA
(29.26M) (27.14M) (23.78M) (19.23M)
EBITDA Growth
-21.35% +7.25% +12.37% +19.13%
EBITDA Margin
-3,145.81% -1,620.00% -421.61% -225.94%

Snapshot

Average Recommendation BUY Average Target Price 2.50
Number of Ratings 1 Current Quarters Estimate -0.26
FY Report Date 12 / 2025 Current Year's Estimate -1.35
Last Quarter’s Earnings 0.444 Median PE on CY Estimate N/A
Year Ago Earnings -0.62 Next Fiscal Year Estimate -1.00
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 1 N/A 1 1
Mean Estimate -0.26 N/A -1.35 -1.00
High Estimates -0.26 N/A -1.35 -1.00
Low Estimate -0.26 N/A -1.35 -1.00
Coefficient of Variance N/A N/A N/A N/A

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 1 1 1
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Evogene Ltd in the News